Cebranopadol clears Phase 3 pain trial, Adneuris licenses China rights
ALLEVIATE-1 hit its pain-reduction endpoint against placebo after abdominoplasty, and Adneuris paired the readout with a Greater China license as it prepares an FDA filing.
Executive Summary
- Adneuris Therapeutics' Phase 3 trial of cebranopadol in postoperative pain met its primary endpoint, showing a pain reduction against placebo over the measured window.
- The result underpins the company's plan to submit a New Drug Application to the FDA later this year for acute pain, and it accompanies the program's first licensing deal outside the United States.
- Cebranopadol works through a dual receptor mechanism that has no direct comparator among postoperative pain competitors, leaving this readout as the reference point for that approach in the indication.
- The topline disclosure describes a pain reduction without the underlying effect size or statistical detail, leaving the magnitude of benefit to be established as fuller data emerge.
The result
ALLEVIATE-1 (NCT06545097), a Phase 3 trial of cebranopadol following abdominoplasty, completed with 279 patients analyzed against its 279-patient target. The registered primary endpoint, Pain NRS AUC4-48, measuring pain intensity from 4 to 48 hours after surgery, showed a reduction versus placebo, Adneuris disclosed in a July 14, 2026 press release. The company also reported reduced use of opioid rescue medication and sustained pain control in the trial, with a safety profile it characterized as consistent with the drug's known profile. NCT06545097+1A Study of Cebranopadol for the Treatment of Acute Pain After AbdominoplastyNCT06545097Adneuris Therapeutics Grants Exclusive License to Zhejiang Conba Pharmaceutical to Advance ...Jul 14, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The deal attached
Adneuris paired the readout with its first ex-U.S. licensing transaction, granting Zhejiang Conba Pharmaceutical Co., Ltd. exclusive rights to develop and commercialize cebranopadol for acute pain across mainland China, Hong Kong, Macao and Taiwan. Conba will pay $17.5 million upfront plus more than $100 million in development and commercial milestones, with tiered double-digit royalties on net sales. "Postoperative pain remains poorly managed for millions of patients here, and existing options often force a tradeoff between efficacy and safety," said Fan Zhou, president of Zhejiang Conba Pharmaceutical, describing the rationale for the deal. Adneuris said it anticipates submitting a New Drug Application to the FDA later in 2026 for acute pain. AdneurisAdneuris Therapeutics Grants Exclusive License to Zhejiang Conba Pharmaceutical to Advance ...Jul 14, 2026
Trial conduct
The trial ran from September 2024 to a primary completion in December 2024, and its registry record shows two primary completion date changes and one enrollment adjustment, from an anticipated 300 patients to an actual 279. Both changes sit within the routine range the trial's own operational model treats as typical, not a departure from plan. The study moved from active status to completed in January 2026, several months after its primary completion date, before the topline result reached the public in July 2026. NCT06545097A Study of Cebranopadol for the Treatment of Acute Pain After AbdominoplastyNCT06545097
Where it sits competitively
Cebranopadol is a dual agonist of the nociceptin/orphanin FQ peptide (NOP) and mu-opioid peptide (MOP) receptors, a mechanism that has no direct comparator among the postoperative pain trials in the field: the nearest analogs, including liposomal bupivacaine, ZYNRELEF, ropivacaine and other small-molecule agents in Phase 2 through Phase 4 testing, all work through different targets such as voltage-gated sodium channels, COX enzymes, or single-receptor opioid mechanisms. That places the ALLEVIATE-1 result as the reference data point for this dual-receptor approach in postoperative pain rather than one entry in a mechanistically converged field.
What's next
Adneuris said it will submit a New Drug Application for cebranopadol to the FDA later in 2026 for treatment of acute pain. The company's broader clinical program for cebranopadol has enrolled more than 2,400 participants across trials including a companion Phase 3 study, ALLEVIATE-2, in patients following bunionectomy. AdneurisAdneuris Therapeutics Grants Exclusive License to Zhejiang Conba Pharmaceutical to Advance ...Jul 14, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.